Announced 30 Oct 2026 · Sources checked
The lawsuit
A Pittsburgh-area woman who was hospitalized in June for two weeks of inpatient treatment following a suicide attempt, and who later provided sensitive medical information during a follow-up clinic visit, is suing Allegheny Health Network and Highmark. The lawsuit, filed October 30 in Allegheny County Common Pleas Court, alleges that the health systems used Abridge, an AI ambient-documentation tool, to record her conversations with clinicians without proper disclosure or consent.
The suit says the plaintiff was told an AI tool would be used but was not informed that the tool would record the entire conversation, that the recording would be transmitted to Abridge AI Inc.'s servers, or that the company would retain and use the recordings for its own commercial purposes. 'A reasonable patient hearing that disclosure would understand the AI to be part of defendants' own systems, operating within the same circle of confidentiality as her clinician and her medical chart,' the complaint states.
The technology
Abridge is an ambient-documentation platform: when activated, it records the full conversation between patient and clinician, sends the audio to Abridge's servers for processing, and returns a draft clinical note that is folded into the patient's electronic medical record. AHN began using Abridge in 2024, and it has expanded to approximately 400 AHN providers across more than 40 specialties. Highmark began using it in August 2025.
Once a conversation is used to train a model, it cannot be taken back. The plaintiff cites Abridge's valuation at $5.3 billion in June 2025 — nearly double what it had been four months earlier — arguing that each patient visit contributed incrementally to that growth and that patients received no share, were not informed, and did not consent.
The legal claims
The lawsuit asserts that Pennsylvania law forbids recording a conversation unless every party has given prior consent — which did not happen here. The complaint includes claims for violations of Pennsylvania wiretap laws, breach of doctor-patient confidentiality, common law invasion of privacy, negligence, breach of implied contract, unjust enrichment, and violations of HIPAA.
The suit seeks to be declared a class action and requests an injunction prohibiting the defendants from using Abridge or any similar recording technology without providing clear disclosure and obtaining informed consent, as well as monetary damages. Similar lawsuits have been filed in California against other health systems over Abridge use.
Why it matters
The case tests a central tension in AI-integrated healthcare: ambient-documentation tools reduce clinician documentation burden, let doctors focus on patients rather than typing, and are increasingly common — Abridge is deployed across more than 300 health systems covering over 250 million patients. But the consent framework has not kept pace with deployment.
The Pennsylvania case (and similar California cases) will establish what level of disclosure is required when a third-party AI company processes confidential medical audio recordings. If the plaintiffs prevail, health systems may need to overhaul consent practices, halt ambient-recording programs, or reconfigure data-sharing with AI vendors — which could slow adoption of a technology many clinicians find valuable.
Caveats
The claims are allegations that have not been tested in court; AHN and Highmark declined to comment. Similar lawsuits are at early stages in California and outcomes may differ across jurisdictions. Abridge is not named as a defendant in the suit, only the health systems deploying the tool.
AI Lookout covered the TribLive report on the lawsuit; it did not independently review the complaint.
What disclosure would be sufficient
The lawsuit's central claim is that 'a passing reference to AI' is not the same as disclosure. The plaintiff argues that to meet the standard of informed consent, patients must be told: that the tool records audio, that the recording leaves the building to a third-party company, that the company retains and may use the data for its own purposes, and that the patient has the right to opt out without affecting care.
None of those elements were communicated in this case, the suit says. The complaint argues that a reasonable patient told that AI is being used would assume the AI is part of the health system's own infrastructure — operating within the same circle of confidentiality — not that a separate commercial company with a $5.3 billion valuation would be receiving, retaining and profiting from the recording of their most private disclosures.
The broader consent gap
The case exposes what happens when a technology with real clinical value — ambient documentation reduces physician burnout and improves note accuracy — is deployed without the consent framework catching up. Abridge's own recommendations ask clinicians to follow their organization's disclosure and consent policies, but the lawsuit alleges that the health systems did not implement adequate processes.
For the AI industry, the lesson is that consent infrastructure is a product requirement, not an afterthought. Companies building clinical AI tools that process patient data need to ensure their customer health systems have clear disclosure scripts, opt-out mechanisms and vendor-data-use policies in place. The lawsuits are already being filed, and the regulatory landscape will follow.
Common questions
What is Abridge?
An AI ambient-documentation platform that records patient-clinician conversations, sends audio to external servers, and returns a draft clinical note.
What laws does the lawsuit allege were broken?
Pennsylvania wiretap law, HIPAA, doctor-patient confidentiality, invasion of privacy, negligence and unjust enrichment.
How widespread is Abridge?
Used by more than 300 health systems covering over 250 million patients. Valued at $5.3 billion.
Sources & further reading
How this story was made
Written by Kristian Kostov with AI assistance and checked against the linked sources. Company performance claims are attributed to the company. Analysis reflects AiLookout’s interpretation; we have not independently tested the products discussed. The cover is an AI-generated editorial illustration, not a photograph or evidence of an actual event.
Our editorial standards
